Clear Cell Renal Cell Carcinoma, Diagnostic and Therapeutic Difficulties, Case Report and Literature Review

Medicina (Kaunas). 2022 Sep 22;58(10):1329. doi: 10.3390/medicina58101329.

Abstract

Nephroblastoma is the most common kidney tumour in children, constitutes about 85% of cases. Although renal cell carcinoma (RCC) is the second-most common kidney malignancy in children, it constitutes only about 2-6% of all cases. Currently, the basis of children's RCC treatment is Umbrella Protocol of SIOP-RTSG, but, due to the rare diagnosis of this neoplasm in children, in difficult cases, treatment is based on the experience in adult patients with RCC. Nephrectomy improves prognosis and is usually performed at the first step of treatment. Acute kidney injury secondary to urolithiasis in a patient after nephrectomy due to RCC is a unique, very serious complication. Study design: We present a case of a 10-year-old boy with metastatic clear cell renal cell carcinoma (ccRCC) of the right kidney and an acute renal failure of the left kidney secondary to uric acid nephrolithiasis. Partial regression of the spread of ccRCC after 12.5-month treatment with sunitinib, followed by progression being observed and satisfactory effects and tolerance of nivolumab were observed later. Comorbidity of acute kidney injury during nephrolithiasis and ccRCC after nephrectomy in children is unique. Drugs used in the treatment clear cell carcinoma in adults (sunitinib and nivolumab), are also used in children with ccRCC.

Keywords: children; clear cell renal cell carcinoma; nephrolithiasis; nivolumab; sunitinib.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Acute Kidney Injury*
  • Adult
  • Carcinoma, Renal Cell* / diagnosis
  • Carcinoma, Renal Cell* / surgery
  • Child
  • Humans
  • Kidney Neoplasms* / diagnosis
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / surgery
  • Male
  • Nephrolithiasis*
  • Nivolumab / therapeutic use
  • Sunitinib / therapeutic use
  • Uric Acid

Substances

  • Sunitinib
  • Nivolumab
  • Uric Acid

Grants and funding

This research received no external funding.